{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:40:20Z","timestamp":1772797220584,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.purol.2020.12.012","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T10:18:13Z","timestamp":1611742693000},"page":"324-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["P\u00e9nurie en souche de BCG entre 2012\u00a0et 2014\u00a0: \u00e9valuation de son impact sur la prise en charge des patients pr\u00e9sentant une TVNIM de haut risque"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-9684","authenticated-orcid":false,"given":"L.","family":"Surlemont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-X.","family":"Nouhaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Delcourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Defortescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-N.","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-4468","authenticated-orcid":false,"given":"C.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.purol.2020.12.012_bib0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.purol.2008.03.002","article-title":"Les \u00ab\u00a0tumeurs superficielles de vessie\u00a0\u00bb n\u2019existent plus","volume":"18","author":"Irani","year":"2008","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2020.12.012_bib0135","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1\u00a0bladder cancer using EORTC risk tables: a combined analysis of 2596\u00a0patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.12.012_bib0140","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2020.12.012_bib0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0160","series-title":"CCAFU \u2014\u00a0ANSM\u00a0: tensions d\u2019approvisionnement en sp\u00e9cialit\u00e9s pour instillations intra-v\u00e9sicales \u00e0 base de BCG (Immucyst, BCG-Medac et OncoTICE)\u00a0: recommandations temporaires pour assurer la continuit\u00e9 des soins","year":"2014"},{"issue":"Suppl 2","key":"10.1016\/j.purol.2020.12.012_bib0165","first-page":"S103","article-title":"Recommandations en onco-urologie 2013\u00a0: tumeurs de la vessie","volume":"24","author":"Pfister","year":"2013","journal-title":"Prog Urol"},{"issue":"13","key":"10.1016\/j.purol.2020.12.012_bib0170","first-page":"26","article-title":"Impact de la p\u00e9nurie de BCG endo-v\u00e9sical sur le nombre de cystectomies et r\u00e9sections r\u00e9alis\u00e9es en France","volume":"27","author":"Larre","year":"2017","journal-title":"Prog Urol 2017"},{"key":"10.1016\/j.purol.2020.12.012_bib0175","article-title":"Recurrence rate and cost consequences of the shortage of Bacillus Calmette Guerin Connaught stain for bladder cancer patients","author":"Ourfali","year":"2019","journal-title":"Eur Urol Foc"},{"issue":"4","key":"10.1016\/j.purol.2020.12.012_bib0180","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1\u00a0and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.purol.2020.12.012_bib0185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","article-title":"Recommandations du Comit\u00e9 de canc\u00e9rologie de l\u2019association fran\u00e7aise d\u2019urologie (CCAFU) pour la bonne pratique des instillations endo-v\u00e9sicales de BCG et de mytomycine C dans le traitement des tumeurs de vessie n\u2019envahissant pas le muscle (TVNIM)","volume":"22","author":"Roupret","year":"2012","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.purol.2020.12.012_bib0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of third dose BCG maintenance therapy every 3\u00a0or 6\u00a0months: two years results of URO-BCG 4\u00a0phase III multicenter study (CCAFU)","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.12.012_bib0195","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.12.012_bib0200","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.12.012_bib0205","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.purol.2020.12.012_bib0210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CAD.0000000000000456","article-title":"Final results of the phase III URO-BCG 4\u00a0multicenter study: efficacy and tolerance of one-third dose BCG maintenance in non-muscle invasive bladder cancer","volume":"28","author":"Nouhaud","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.purol.2020.12.012_bib0215","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1\u00a0papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2020.12.012_bib0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.purol.2015.10.011","article-title":"Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Gu\u00e9rin (BCG): review by the French Urological Association Oncology Committee","volume":"26","author":"Neuzillet","year":"2016","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0225","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second trans-urethral resection on the long-term outcome of patients with newly diagnosed pT1\u00a0urothelial carcinoma with respect to recurrence, progression rate and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0230","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of non-muscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2020.12.012_bib0240","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.purol.2014.01.001","article-title":"Quelle place pour l\u2019\u00e9valuation endoscopique avec fluorescence (Hexvix\u00ae) apr\u00e8s traitement d\u2019attaque par instillations endo-v\u00e9sicales de BCG","volume":"24","author":"Charbit","year":"2014","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0245","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2020.12.012_bib0250","series-title":"Tumeurs de la vessie\u00a0: point CCAFU et ANSM sur les recommandations de prise en charge par BCG Medac\u00ae\/Oncotice\u00ae","year":"2020"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708720307600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708720307600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:34:18Z","timestamp":1761114858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708720307600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1166708720307600"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2020.12.012","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P\u00e9nurie en souche de BCG entre 2012\u00a0et 2014\u00a0: \u00e9valuation de son impact sur la prise en charge des patients pr\u00e9sentant une TVNIM de haut risque","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}